| Overview |
| bs-3654R-Cy3 |
| FPRL1 Polyclonal Antibody, Cy3 Conjugated |
| WB, FCM, IF(ICC) |
| Human, Mouse, Rat |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human FPRL1 |
| 51-150/351 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 2358 |
| P25090 |
| Cell membrane |
| ALXR; HM63; FMLPX; FPR2A; FPRH1; FPRH2; FPRL1; LXA4R; FMLP-R-II; N-formyl peptide receptor 2; FMLP-related receptor I; FMLP-R-I; Formyl peptide receptor-like 1; Lipoxin A4 receptor; LXA4 receptor; RFP; FPR2 |
| Low affinity receptor for N-formyl-methionyl peptides, which are powerful neutrophils chemotactic factors. Binding of FMLP to the receptor causes activation of neutrophils. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. The activation of LXA4R could result in an anti-inflammatory outcome counteracting the actions of proinflammatory signals such as LTB4 (leukotriene B4). |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(ICC) |
1:50-200 |
Powered by Bioz